Topic List : Genetics
Mildred Cho to co-lead new biomedical ethics hub
The new center, funded by a $7.1 million award from the National Human Genome Research Institute, will collect and share research on the ethical, legal and social implications of genomics.
Dennis Wall on new discoveries in autism genetics
Wall discusses how he and his collaborators used whole-genome data from hundreds of families affected by autism to identify 16 new autism risk genes and a rare genetic syndrome that explains some cases of the disorder.
Genetics of protein aggregates in ALS
Stanford researchers identified a gene crucial to the formation of toxic proteins in amyotrophic lateral sclerosis and showed how it could inform potential therapies for the disease.
Immune cells speed aging brains’ demise
Stanford researchers have found intrusive immune cells in a place in the brains of humans and older mice where new nerve cells are born. The intruders appear to impair nerve cell generation.
Gene networks and heart failure
A Stanford-led research team has mapped out a network of gene activity before and after heart failure to better understand how heart health declines.
Increasing diversity in genome studies
Data scientist Genevieve Wojcik speaks about the lack of diversity in genomewide association studies, why it’s a problem and how increasing diversity in these studies can elevate the entire population.
Using RNA for rare-disease diagnosis
Geneticist Stephen Montgomery explains why the transcriptome, the collection of RNA molecules in a cell, is a crucial piece of deciphering the source of rare diseases.
Revealing health through big data
Years-long tracking of individuals’ biology helped define what it meant for them to be healthy and showed how changes from the norm could signal disease, a Stanford-led study reports.
Helping with NASA twins study
Stanford scientists and their collaborators found markers of immune-related stress and other molecular changes in the body of NASA astronaut Scott Kelly.
Possible ‘bubble boy’ disease therapy
In preclinical trials, Stanford scientists and their collaborators harnessed the gene-editing system CRISPR-Cas9 to replace the mutated gene underpinning the devastating immune disease.